Duraibabu Prathyusha has filed 26 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 48828 shares of Organogenesis Holdings Inc. ($ORGO) on February 18, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2026 | Organogenesis Holdings Inc. | $ORGO | Duraibabu Prathyusha | Director | A | Class A Common Stock | 48828 | $0.00 | 247,047.0000 | 130,848,995 | 24.63% | 0.04% |
| Jan. 22, 2026 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | F | Common Stock | 36676 | $0.40 | 660,042.0000 | 336,494,489 | 5.26% | 0.01% |
| Nov. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | F | Common Stock | 2544 | $0.42 | 696,718.0000 | 336,494,489 | 0.36% | 0.00% |
| Oct. 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | PRINCIPAL FINANCIAL OFFICER | F | Common Stock | 45225 | $0.66 | 699,262.0000 | 224,710,019 | 6.07% | 0.02% |
| Aug. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1792 | $0.59 | 744,487.0000 | 224,710,019 | 0.24% | 0.00% |
| July 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 31866 | $0.48 | 746,279.0000 | 224,710,019 | 4.10% | 0.01% |
| May 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1792 | $0.47 | 778,145.0000 | 224,710,019 | 0.23% | 0.00% |
| April 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 31866 | $0.78 | 779,937.0000 | 224,710,019 | 3.93% | 0.01% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | A | Stock Option (Right to Buy) | 560000 | $0.00 | 560,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | A | Common Stock | 120000 | $0.00 | 811,803.0000 | 0 | 17.35% | 0.00% |
| Feb. 25, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1375 | $0.96 | 691,803.0000 | 0 | 0.20% | 0.00% |
| Feb. 24, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1792 | $1.00 | 693,178.0000 | 0 | 0.26% | 0.00% |
| Feb. 19, 2025 | Organogenesis Holdings Inc. | $ORGO | Duraibabu Prathyusha | Director | A | Class A Common Stock | 49575 | $0.00 | 198,219.0000 | 131,673,278 | 33.35% | 0.04% |
| Jan. 22, 2025 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 129242 | $1.15 | 694,970.0000 | 0 | 15.68% | 0.00% |
| Nov. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1371 | $1.94 | 824,212.0000 | 0 | 0.17% | 0.00% |
| Nov. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1787 | $1.88 | 825,583.0000 | 0 | 0.22% | 0.00% |
| Aug. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1371 | $0.86 | 827,370.0000 | 0 | 0.17% | 0.00% |
| Aug. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1787 | $0.86 | 828,741.0000 | 0 | 0.22% | 0.00% |
| June 11, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 892 | $0.61 | 830,528.0000 | 0 | 0.11% | 0.00% |
| May 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1371 | $0.60 | 831,420.0000 | 0 | 0.16% | 0.00% |
| May 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 1787 | $0.60 | 832,791.0000 | 0 | 0.21% | 0.00% |
| Feb. 25, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 3453 | $1.13 | 834,578.0000 | 0 | 0.41% | 0.00% |
| Feb. 24, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | F | Common Stock | 5474 | $1.13 | 838,031.0000 | 0 | 0.65% | 0.00% |
| Feb. 21, 2024 | Organogenesis Holdings Inc. | $ORGO | Duraibabu Prathyusha | Director | A | Class A Common Stock | 51020 | $0.00 | 148,644.0000 | 132,746,727 | 52.26% | 0.04% |
| Jan. 22, 2024 | SANGAMO THERAPEUTICS, INC | $SGMO | Duraibabu Prathyusha | SVP, CHIEF FINANCIAL OFFICER | A | Common Stock | 712500 | $0.00 | 843,505.0000 | 0 | 543.87% | 0.00% |
| Feb. 22, 2023 | Organogenesis Holdings Inc. | $ORGO | Duraibabu Prathyusha | Director | A | Class A Common Stock | 65737 | $0.00 | 97,624.0000 | 132,383,152 | 206.16% | 0.05% |